Related Experiment Video

Updated: Apr 4, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K

Single nucleotide polymorphisms for genes encoding cytokines in the context of cardiac surgery. Part I: Heart

Aleksander Danikiewicz1, Janusz Szkodzinski2, Bartosz Hudzik2

  • 1Department for the Prevention of Food-related Diseases, School of Public Health, Medical University of Silesia, Katowice, Poland.

Kardiochirurgia I Torakochirurgia Polska = Polish Journal of Cardio-Thoracic Surgery
|September 4, 2015
PubMed

Insights

Genetic markers for cytokine genes, including IL-2, IL-4, IL-6, IL-10, TGF-β1, PDGF, VEGF, and TNF-α, show promise for predicting heart transplant rejection. While not yet clinically applicable, these single nucleotide polymorphisms (SNPs) may personalize future treatments.

Area of Science:

  • Cardiovascular research
  • Immunogenetics
  • Transplantation medicine

Background:

  • Cardiovascular diseases are a leading cause of death in the EU.
  • Heart transplantation is the primary treatment for end-stage heart failure.
  • Graft rejection occurs in 20-30% of heart transplant recipients within six months, despite immunosuppression.

Purpose of the Study:

  • To investigate the role of cytokine gene single nucleotide polymorphisms (SNPs) in heart transplantation.
  • To explore potential molecular markers for assessing rejection risk.
  • To evaluate the future clinical utility of genetic testing in transplant patients.

Main Methods:

  • Analysis of single nucleotide polymorphisms (SNPs) in cytokine genes: IL-2, IL-4, IL-6, IL-10, TGF-β1, PDGF, VEGF, and TNF-α.
  • Correlation of specific SNPs with outcomes in heart transplant recipients.
  • Review of existing research on genetic markers and immune response in transplantation.

Main Results:

  • The study examined SNPs in key cytokine genes (IL-2, IL-4, IL-6, IL-10, TGF-β1, PDGF, VEGF, TNF-α) related to heart transplantation.
  • Current data does not support the reliable clinical application of these genetic tests.
  • Preliminary findings suggest a potential role for these SNPs in future personalized treatment strategies.

Conclusions:

  • Cytokine gene SNPs represent a promising area for improving heart transplant outcomes.
  • Further research is needed to validate these genetic markers for clinical use.
  • Individualized treatment approaches based on genetic profiles may enhance patient care post-transplantation.

Keywords:
SNPcytokinesheart transplantationsingle nucleotide polymorphisms

More Related Videos

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model06:45

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model

Published on: February 7, 2022

4.4K
Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique10:32

Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique

Published on: October 12, 2014

15.1K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86